Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting myeloid cells in the tumor sustaining microenvironment
Jonathan Schupp, Franziska K. Krebs, Niklas Zimmer, et al.
Cellular Immunology (2017) Vol. 343, pp. 103713-103713
Closed Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

Targeting Tumor Microenvironment for Cancer Therapy
Catarina Roma‐Rodrigues, Rita Mendes, Pedro V. Baptista, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 4, pp. 840-840
Open Access | Times Cited: 1024
Next generation of immune checkpoint inhibitors and beyond
Julian A. Marin‐Acevedo, ErinMarie O. Kimbrough, Yanyan Lou
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 448
DNA Vaccines—How Far From Clinical Use?
Dominika Hobernik, Matthias Bros
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3605-3605
Open Access | Times Cited: 429
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments
Zhennan Yuan, Yingpu Li, Sifan Zhang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 368
MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer
Yueh‐Shan Weng, Hong‐Yu Tseng, Yen‐An Chen, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 350
Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets
Yoon Mee Yang, Sohee Kim, Ekihiro Seki
Seminars in Liver Disease (2019) Vol. 39, Iss. 01, pp. 026-042
Open Access | Times Cited: 344
Tumor microenvironment components: Allies of cancer progression
Pablo Igor Ribeiro Franco, Arthur Perillo Rodrigues, Liliana Borges de Menezes, et al.
Pathology - Research and Practice (2019) Vol. 216, Iss. 1, pp. 152729-152729
Closed Access | Times Cited: 201
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment
Maximilian Haist, Henner Stege, Stephan Grabbe, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 210-210
Open Access | Times Cited: 138
YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells
Shoubao Ma, Baofa Sun, Songqi Duan, et al.
Nature Immunology (2023) Vol. 24, Iss. 2, pp. 255-266
Open Access | Times Cited: 119
A novel golgi related genes based correlation prognostic index can better predict the prognosis of glioma and responses to immunotherapy
Beichuan Zhao, Ruoheng Xuan, Guitao Yang, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Dissecting intratumoral myeloid cell plasticity by single cell RNA‐seq
Qianqian Song, Gregory A. Hawkins, L. James Wudel, et al.
Cancer Medicine (2019) Vol. 8, Iss. 6, pp. 3072-3085
Open Access | Times Cited: 135
Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction
Mingzhu Yin, Ying Guo, Rui Hu, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 133
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
Nadine S. Jahchan, Adriana M. Mujal, Joshua L. Pollack, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 112
Abscopal effect in radioimmunotherapy
Milad Ashrafizadeh, Bagher Farhood, Ahmed Eleojo Musa, et al.
International Immunopharmacology (2020) Vol. 85, pp. 106663-106663
Closed Access | Times Cited: 112
Macrophage-Targeted Therapeutics for Metabolic Disease
Kristin R. Peterson, Matthew A. Cottam, Arion Kennedy, et al.
Trends in Pharmacological Sciences (2018) Vol. 39, Iss. 6, pp. 536-546
Open Access | Times Cited: 110
Targeting Tumor Microenvironment by Small-Molecule Inhibitors
Shangwei Zhong, Ji-Hak Jeong, Zhikang Chen, et al.
Translational Oncology (2019) Vol. 13, Iss. 1, pp. 57-69
Open Access | Times Cited: 110
Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Robyn D. Gartrell, Douglas K. Marks, Thomas D. Hart, et al.
Cancer Immunology Research (2018) Vol. 6, Iss. 4, pp. 481-493
Open Access | Times Cited: 99
Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective
Gonçalo S. Clemente, Aren van Waarde, Inês F. Antunes, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 15, pp. 5291-5291
Open Access | Times Cited: 99
Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
Tiziana Triulzi, Viola Regondi, Loris De Cecco, et al.
British Journal of Cancer (2018) Vol. 119, Iss. 12, pp. 1487-1494
Open Access | Times Cited: 90
The CCR2+ Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers
Matthias Bartneck, Peter L. Schrammen, Diana Möckel, et al.
Cellular and Molecular Gastroenterology and Hepatology (2018) Vol. 7, Iss. 2, pp. 371-390
Open Access | Times Cited: 89
β2 Integrins—Multi-Functional Leukocyte Receptors in Health and Disease
Monika Bednarczyk, Henner Stege, Stephan Grabbe, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1402-1402
Open Access | Times Cited: 86
Blocking immunosuppressive neutrophils deters pY696-EZH2–driven brain metastases
Lin Zhang, Jun Yao, Yongkun Wei, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 545
Open Access | Times Cited: 85
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Paola Ciciola, Priscilla Cascetta, Cataldo Bianco, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 3, pp. 675-675
Open Access | Times Cited: 78
Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology
Ernesto Bockamp, Sebastian Rosigkeit, Dominik Siegl, et al.
Cells (2020) Vol. 9, Iss. 9, pp. 2102-2102
Open Access | Times Cited: 77
Porphyromonas gingivalis promotes tumor progression in esophageal squamous cell carcinoma
Miao‐Fen Chen, Ming‐Shian Lu, Ching‐Chuan Hsieh, et al.
Cellular Oncology (2020) Vol. 44, Iss. 2, pp. 373-384
Closed Access | Times Cited: 71
Page 1 - Next Page

Scroll to top